ValiRx plc

Equities

VAL

GB00BLH13C52

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:40:16 2024-05-17 am EDT			5-day change	1st Jan Change
2.2 ^GBX	+15.79%		-27.87%	-62.71%

May. 16	EARNINGS AND TRADING: Tullow Oil on track to hit free cash flow target	AN
May. 15	Vertu Motors ups dividend as hails record revenue	AN

ValiRx plc Announces Board Changes

April 14, 2020 at 07:41 am EDT

ValiRx plc announced that resolution to remove Satu Vainikka as a director was passed. As a consequence of the passing of the resolution, Satu Vainikka is no longer a director of the Company. The Company also announced that George Morris had tendered his resignation, which had been accepted by the board, consequently he is no longer a director of the Company and Resolution 1 has been withdrawn.

Latest news about ValiRx plc

EARNINGS AND TRADING: Tullow Oil on track to hit free cash flow target	May. 16	AN
Vertu Motors ups dividend as hails record revenue	May. 15	AN
AIM WINNERS & LOSERS: Itim up on Majestic Wine contract renewal	May. 15	AN
ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2023	May. 15	CI
Valirx plc Reiterates Earnings Guidance for the Year 2024	Apr. 24	CI
Valirx plc Announces Directorate Changes	Apr. 22	CI
ValiRx inks evaluation deal with Imperial College London for research	Mar. 21	AN
ValiRx plc Announces Signature of an Evaluation Agreement with Imperial College London	Mar. 21	CI
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	Mar. 19	AN
ValiRx Kick off Search for New CEO	Mar. 19	MT
Valirx plc Announces Board Appointments, Subject to Completion of Regulatory Due Diligence	Mar. 19	CI
EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout	Feb. 29	AN
Valirx plc Intends to Appoint Martin Gouldstone as Non-Executive Director	Feb. 29	CI
ValiRx Says Shareholder Group's Requisition Notice Invalid	Feb. 13	MT
ValiRx says requisition notice from shareholder group is invalid	Feb. 13	AN
ValiRx signs research sharing deal with Dundee University	Feb. 12	AN
Valirx Signs Research, Evaluation Agreements with University of Dundee	Feb. 12	MT
ValiRx plc Announces Agreement with Dundee Uni and Project Initiation	Feb. 12	CI
ValiRx receives shareholder request for board change	Feb. 09	AN
ValiRx plc Announces Resignation of Stella Panu as A Non-Executive Director, Effective from 15 April 2024	Jan. 18	CI
ValiRx raises GBP192,200, part of wider GBP1.8 million raise	Dec. 19	AN
Good Energy says ZapMap expands into mainland Europe	Dec. 13	AN
ValiRx Signs Licensing Option Deal with Ambrose Healthcare	Dec. 05	MT
ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose	Dec. 05	AN
AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises	Dec. 05	AN

Chart ValiRx plc

Duration

Period

More charts

Company Profile

ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALIRX PLC	-62.71%	3.19M
VERTEX PHARMACEUTICALS INCORPORATED	+9.09%	114B
REGENERON PHARMACEUTICALS, INC.	+11.47%	104B
BIONTECH SE	-13.01%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-3.24%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+8.07%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.91%	12.55B

Bio Therapeutic Drugs